Should You Buy Shares of CRISPR Therapeutics in February?

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics ...

Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors

SOUTH SAN FRANCISCO, Calif. & MADISON, Wis., February 18, 2026--Cellares, the first Integrated Development and Manufacturing ...